In a phase 3 trial in Non‑Erosive GERD, the safety profile of VOQUEZNA was comparable to placebo1
| ADVERSE REACTIONS REPORTED IN ≥2% OF ADULT PATIENTS IN THE VOQUEZNA ARM IN THE 4‑WEEK STUDY | ||
|---|---|---|
| Adverse Reactions | VOQUEZNA 10 mg ONCE DAILY * | Placebo ONCE DAILY * |
| Abdominal pain† | 2% | 2% |
| Constipation | 2% | 1% |
| Diarrhea | 2% | 1% |
| Nausea | 2% | <1% |
| Urinary tract infection | 2% | 1% |
Other adverse reactions: upper respiratory tract infection (4%) and sinusitis (3%) were reported in patients who received VOQUEZNA 10 mg once daily in the 20‑week extension phase.1
*Represents safety population.
†Represents a grouped term and includes related terms.1